Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urapidil, a multiple-action alpha-blocking drug.

B N Prichard1, B Tomlinson, J C Renondin

  • 1Department of Clinical Pharmacology, University College and Middlesex School of Medicine, London, United Kingdom.

The American Journal of Cardiology
|August 15, 1989
PubMed
Summary

Urapidil effectively lowers blood pressure through peripheral alpha-1 blockade and potential central sympathetic inhibition. Further research is needed to clarify its beta-blocking effects and impact on heart rate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

86 Creating homozygous offspring using oviductal sperm deposition with poor quality cryopreserved semen from a transgenic founder goat.

Reproduction, fertility, and development·2022
Same author

Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoin.

Hong Kong medical journal = Xianggang yi xue za zhi·2018
Same author

Nivolumab before and after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2017
Same author

Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.

Journal of clinical pharmacy and therapeutics·2016
Same author

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.

Bone marrow transplantation·2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Urapidil exhibits multiple pharmacological actions in animal studies, suggesting potential antihypertensive effects.
  • These actions include alpha-1 blockade, weak beta-1 blockade, serotonin receptor interaction, and central sympathetic tone depression.

Purpose of the Study:

  • To investigate the antihypertensive mechanisms of urapidil in humans.
  • To evaluate its pharmacokinetic profile and receptor interactions.

Main Methods:

  • Human studies assessed peripheral alpha-1 blockade via dose-response curves to phenylephrine.
  • Pharmacokinetic analysis determined oral bioavailability and half-life.
  • Hemodynamic studies examined effects on blood pressure, heart rate, and cardiac output.

Related Experiment Videos

Main Results:

  • Peripheral alpha-1 blockade was confirmed in humans, reducing peripheral resistance and arterial pressure.
  • Oral bioavailability is approximately 70% with a 4-hour peak concentration time.
  • Evidence for significant beta-1 blocking activity and consistent effects on heart rate is marginal; central effects on blood pressure and heart rate were observed.

Conclusions:

  • Urapidil's primary antihypertensive effect in humans is attributed to peripheral alpha-1 blockade.
  • Central mechanisms may also contribute, though beta-1 blocking effects are weak and inconsistent.
  • Pharmacokinetic properties support its oral efficacy.